- Home / RMA Access Center
Ongoing Clinical Trials studies
NOVO Nordisk Trial
Sponsor: Novo Nordisk
Protocol: NN9535-4321 (Phase-3b) (Non-dialysis)
A randomized Double-blind, Event – driven, Placebo controlled, multicenter study of the Effect of Semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease. Open for Enrollment:
Protocol: ID-080A305 (Phase-3) (Non-dialysis)
Multi-center, Double-blinded, randomized study with aprocitentan in subjects with uncontrolled blood pressure and chronic kidney disease stage 3 or 4.
Sponsor: Akebia Therapeutics
Protocol: AKB-6548-CI (Phase-3) (Non-dialysis)
A Randomized, Open-label, Active-controlled study evaluating the Efficacy and Safety of Oral Vadadustat for the correction of Anemia in subjects with non -dialysis and dialysis dependent Chronic Kidney Disease.
Sponsor: Cara Therapeutics
Protocol: CR845-CLIN3101, 3102 and 3103 (Phase 3) (Dialysis)AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS.
- Choosing a selection results in a full page refresh.
- Press the space key then arrow keys to make a selection.